Sol-Gel Technologies (SLGL) had announced that it achieved positive results from its two pivotal studies using Twyneo to treat patients with acne vulgaris. The company prides itself on its drug delivery technology, microencapsulation, which is able to deliver topical treatments for these patients. The downside is that an NDA won't be submitted to the FDA for regulatory approval until 2nd half of 2020 for Twyneo. That would mean doctors and patients may not have their hands on such a treatment until 2nd half of 2021. There is another product in the pipeline known as Epsolay,